Sample
Plasma, serum, culture media, tissue homogenate, CSF, urine, or any biological fluid
Intended Use
This kit is designed to measure the concentration of a specifi c peptide and its related peptides based on the principle of a "competitive" enzyme immunoassay.
Contents of Kit
1. EIA assay buffer concentrate (20x, 50ml)
2. Pre-coated EIA plate (96 wells, 1 plate)
3. Acetate plate sealer (APS) (3 pieces)
4. Primary antibody (1 vial)
5. Standard peptide (1 vial)
6. Biotinylated peptide (1 vial)
7. Positive control (2 vials)
8. Streptavidin-horseradish peroxidase (SA-HRP) concentrate (30μl)
9. Substrate solution (12ml)
10. 2N HCl (Stop solution) (15ml)
Storage
1. Store the kit at 4°C upon receipt. Do not freeze.
2. It is highly recommended that all solutions be used as soon as possible after reconstitution.
3. Any unused strips/columns may be removed from the pre-coated immunoplate. Please place strips back in the original zip-lock foil pouch with a dessicant, reseal, and store at 4°C. Do not allow moisture to accumulate on the wells.
4. If necessary, store the 1× assay buffer at 4°C.
5. If necessary, store any reconstituted solutions of standard peptide, biotinylated peptide, antibody and SA-HRP at 4°C
Precision
Intra-assay variation: <10%
Inter-assay variation: <15%
Detection Range
0.08 - 0.86 ng/ml
Citations
Publication ()
Have you cited DEIA-BJ815 in a publication?
Let us know and earn a reward for your research.
Intrinsically Disordered Protein Coating for Oral Delivery of Peptide Drugs
Ney M, Sirohi P, Shmidov Y, Singh A, Wadsworth G, Li X, Zheng J, Peng E, Fan L, Mahendran TS, Deshpande S, Tripathi N, Su JC, Milligan JJ, Wang YX, Banerjee PR, Chilkoti A
Applications: ELISA
Reactive species: Unspecified reactive species
"Abstract: Advancing oral delivery of peptide therapeutics requires innovative materials that overcome gastrointestinal barriers. We introduce the first engineered synthetic intrinsically disordered protein (SynIDP) that self-assembles into an enteric coating, encapsulating peptide drugs to enhance gastric acid resistance and intestinal targeting. This SynIDP recapitulates the molecular design principles and phase transitions of native IDPs to exhibit temperature-controlled condensation and pH-controlled solidification-both transitions being reversible and precisely tuned to intestinal cues. Through detailed analysis of the kinetics of the liquid-to-solid phase transition, we achieve control over the nano-to-microscale morphology of the protein coating, optimizing drug encapsulation and protection. The coating protects peptide-based weight loss drugs for over 60 minutes in simulated gastric conditions, then dissolves to release the active compound. Oral delivery to obese mice results in more consistent weight loss compared to the unencapsulated drug. This modular protein-based coating is a promising platform technology for enhancing oral peptide drug delivery and improving patient compliance."
Article snippet: Serum concentrations were determined using an Exendin-4 (Heloderma suspectum) competition ELISA kits purchased from Creative Diagnostics, in which a standard curve using ExRAC doped into serum was generated for comparison to the Exendin-4 calibration samples. 
Figure 1. Competitive ELISA curves of Exendin-4 antibody binding to ExCDC doped into mouse serum versus the Exendin-4 control. 
Figure 2. Blood levels of Exendin-4 antibody–binding molecules were measured by ELISA using an ExCDC serum standard curve.
COA
Loading ......
